|
|
| Introduction The obesity market is easily characterized as attractive, featuring a booming patient potential needing long term therapy, but repeated product withdrawals and failed pipeline candidates highlight the reality of increasingly cautious regulatory bodies, reluctant payers, and a clinical community that puts more stock in diet and exercise: $513.7m sales in 2008 fall far short of analyst predictions. Reasons to Purchase
|
Related Markets
Drug Discovery Reports
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
- Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2012
- Tachycardia (Tachyarrhythmias) Global Clinical Trials Review, H1, 2012
- Restless Legs Syndrome Global Clinical Trials Review, H1, 2012
- Lung Injury Global Clinical Trials Review, H1, 2012

